Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer

Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis, modifies the effect of statins on serum cholesterol levels. Long-term use of statins is associated with a reduced risk of colorectal cancer (CRC) in some, but not all, studies. We genotyped variants in 40 candidate genes important for cholesterol synthesis and metabolism in a population-based case-control study of CRC involving 2,138 incident cases and 2,049 population-based controls. We identified a single-nucleotide polymorphism in the HMGCR gene that significantly modified the protective association between statins and CRC risk. Compared with nonusers, the unadjusted odds ratio of CRC among statin users with the A/A genotype of rs12654264 in HMGCR was 0.3 (95% confidence interval, 0.18-0.51) and among statin users with the T/T genotype was 0.66 (95% confidence interval, 0.41-1.06; P-interaction = 0.0012). This genetic variant (A/A genotype of rs12654264) also was associated with lower serum levels of low-density lipoprotein among all cases and controls. In colon cancer cell lines, the reduction in cholesterol levels after statin treatment was substantially stronger in cells carrying the A/A genotype, and this difference was related to alternative splicing involving the HMGCR statin-binding domain. We anticipate that these data may advance the development of personalized statin use for reducing the risk of cancer as well as cardiovascular disease among the approximately 25 million people currently using statins worldwide. Cancer Prev Res; 3(5); 597–603. ©2010 AACR.

[1]  Peter Tanuseputro,et al.  Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study , 2006, BMJ : British Medical Journal.

[2]  Harminder Singh,et al.  Long-Term Use of Statins and Risk of Colorectal Cancer: A Population-Based Study , 2009, The American Journal of Gastroenterology.

[3]  Joan Valls,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[4]  C. Tai,et al.  An accurate stepwise electrocardiographic algorithm for localization of accessory pathways in patients with Wolff-Parkinson-White syndrome from a comprehensive analysis of delta waves and R/S ratio during sinus rhythm. , 1995, The American journal of cardiology.

[5]  M. Sabatine,et al.  Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. , 2008, Journal of the American College of Cardiology.

[6]  Michael L. Johnson,et al.  Statins and the Risk of Colorectal Carcinoma: A Nested Case–Control Study in Veterans With Diabetes , 2009, The American Journal of Gastroenterology.

[7]  M. Daly,et al.  Common SNPs in HMGCR in Micronesians and Whites Associated With LDL-Cholesterol Levels Affect Alternative Splicing of Exon13 , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. Lippman,et al.  Cancer prevention: from 1727 to milestones of the past 100 years. , 2009, Cancer research.

[9]  S. Bonovas,et al.  Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Feng Gao,et al.  Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin , 2008, Circulation.

[11]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Effect of Patient Characteristics on Lovastatin‐Induced Changes in Plasma Concentrations of Lipids and Lipoproteins , 1992, Circulation.

[12]  N. Clemenson.  Statins and risk of coronary heart disease. , 2000, JAMA.

[13]  N. Tsuji,et al.  Survivin Down-regulation Plays a Crucial Role in 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor-induced Apoptosis in Cancer* , 2007, Journal of Biological Chemistry.

[14]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[15]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[16]  W. El-Deiry,et al.  Enhanced Sensitivity of G1 Arrested Human Cancer Cells Suggests a Novel Therapeutic Strategy Using a Combination of Simvastatin and TRAIL , 2002, Cell cycle.

[17]  V. Steele,et al.  Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. , 2006, Cancer research.

[18]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[19]  J. Stein,et al.  HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. , 2001, Carcinogenesis.

[20]  A. Zwinderman,et al.  Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. , 1995, The American journal of cardiology.

[21]  Deborah A Nickerson,et al.  Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment , 2008, Circulation.

[22]  B. Kaina,et al.  Lovastatin inhibits Rho‐regulated expression of E‐selectin by TNF‐α and attenuates tumor cell adhesion , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Olle Melander,et al.  Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.

[24]  Jack A. Taylor,et al.  Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. , 1994, Statistics in medicine.

[25]  C. Rao,et al.  Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. , 2002, International journal of oncology.

[26]  M L Simoons,et al.  Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? , 2001, European heart journal.

[27]  A. Palazzuoli,et al.  Time‐dependent effect of statins on platelet function in hypercholesterolaemia , 2002, European journal of clinical investigation.

[28]  D. Gray,et al.  Statin prescribing in Nottingham general practices: a cross-sectional study. , 1999, Journal of public health medicine.

[29]  H. Welch,et al.  Statins and the Risk of Colorectal Cancer , 2005, The New England journal of medicine.

[30]  C. Elson,et al.  Sterol‐independent regulation of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase in tumor cells , 2001, Molecular carcinogenesis.

[31]  C. Rao,et al.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.